Stock Track | Myriad Genetics Soars 5.02% Pre-market on Unveiling of 11 New Genetic Testing Studies

Stock Track11-06

Myriad Genetics (MYGN) saw its stock surge 5.02% in pre-market trading on Thursday, following the announcement of 11 new research studies to be presented at the upcoming National Society of Genetic Counselors (NSGC) 44th Annual Conference. This significant pre-market movement reflects investor optimism about the company's advancements in genetic testing technology and its potential impact on future growth.

The studies, set to be presented on November 7 and 8, 2025, will showcase Myriad Genetics' latest developments across various genetic testing products. These include the MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen, and Foresight® Carrier Screen. The research topics span a wide range, covering RNA analysis in hereditary cancer testing, advancements in prenatal screening, and professional development for genetic counselors.

This announcement demonstrates Myriad Genetics' commitment to innovation and its strong position in the competitive genetic testing market. The positive pre-market reaction suggests that investors are anticipating these research findings to potentially lead to new product developments or improvements, which could strengthen the company's market position and drive future revenue growth. As the conference approaches, market participants will likely keep a close eye on the outcomes of these presentations and their potential implications for Myriad Genetics' business prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131314355?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 21:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131314355","market":"sg","top_or_hot":-1,"title":"Stock Track | Myriad Genetics Soars 5.02% Pre-market on Unveiling of 11 New Genetic Testing Studies","media":"Stock Track","content":"<p>Myriad Genetics (MYGN) saw its stock surge 5.02% in pre-market trading on Thursday, following the announcement of 11 new research studies to be presented at the upcoming National Society of Genetic Counselors (NSGC) 44th Annual Conference. This significant pre-market movement reflects investor optimism about the company's advancements in genetic testing technology and its potential impact on future growth.</p>\n\n<p>The studies, set to be presented on November 7 and 8, 2025, will showcase Myriad Genetics' latest developments across various genetic testing products. These include the MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen, and Foresight® Carrier Screen. The research topics span a wide range, covering RNA analysis in hereditary cancer testing, advancements in prenatal screening, and professional development for genetic counselors.</p>\n\n<p>This announcement demonstrates Myriad Genetics' commitment to innovation and its strong position in the competitive genetic testing market. The positive pre-market reaction suggests that investors are anticipating these research findings to potentially lead to new product developments or improvements, which could strengthen the company's market position and drive future revenue growth. As the conference approaches, market participants will likely keep a close eye on the outcomes of these presentations and their potential implications for Myriad Genetics' business prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Myriad Genetics Soars 5.02% Pre-market on Unveiling of 11 New Genetic Testing Studies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Myriad Genetics Soars 5.02% Pre-market on Unveiling of 11 New Genetic Testing Studies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Myriad Genetics (MYGN) saw its stock surge 5.02% in pre-market trading on Thursday, following the announcement of 11 new research studies to be presented at the upcoming National Society of Genetic Counselors (NSGC) 44th Annual Conference. This significant pre-market movement reflects investor optimism about the company's advancements in genetic testing technology and its potential impact on future growth.</p>\n\n<p>The studies, set to be presented on November 7 and 8, 2025, will showcase Myriad Genetics' latest developments across various genetic testing products. These include the MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen, and Foresight® Carrier Screen. The research topics span a wide range, covering RNA analysis in hereditary cancer testing, advancements in prenatal screening, and professional development for genetic counselors.</p>\n\n<p>This announcement demonstrates Myriad Genetics' commitment to innovation and its strong position in the competitive genetic testing market. The positive pre-market reaction suggests that investors are anticipating these research findings to potentially lead to new product developments or improvements, which could strengthen the company's market position and drive future revenue growth. As the conference approaches, market participants will likely keep a close eye on the outcomes of these presentations and their potential implications for Myriad Genetics' business prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYGN","symbol_name":"万基遗传","start_time":0,"source_url":"","article_id":"1131314355","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131314355","pubTimestamp":1762436458,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Myriad Genetics (MYGN) saw its stock surge 5.02% in pre-market trading on Thursday, following the announcement of 11 new research studies to be presented at the upcoming National Society of Genetic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYGN":"万基遗传"},"translate_title":"个股追踪|公布11项新基因检测研究Myriad Genetics盘前大涨5.02%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"Myriad Genetics (MYGN) saw its stock surge 5.02% in pre-market trading on Thursday, following the announcement of 11 new research studies to be presented at the upcoming National Society of Genetic Counselors (NSGC) 44th Annual Conference. This significant pre-market movement reflects investor optimism about the company's advancements in genetic testing technology and its potential impact on future growth.\nThe studies, set to be presented on November 7 and 8, 2025, will showcase Myriad Genetics' latest developments across various genetic testing products. These include the MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen, and Foresight® Carrier Screen. The research topics span a wide range, covering RNA analysis in hereditary cancer testing, advancements in prenatal screening, and professional development for genetic counselors.\nThis announcement demonstrates Myriad Genetics' commitment to innovation and its strong position in the competitive genetic testing market. The positive pre-market reaction suggests that investors are anticipating these research findings to potentially lead to new product developments or improvements, which could strengthen the company's market position and drive future revenue growth. As the conference approaches, market participants will likely keep a close eye on the outcomes of these presentations and their potential implications for Myriad Genetics' business prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131314355","isCrawlerRequest":true}